-
Mashup Score: 0Chemotherapy: the backbone of lymphoma treatment - 1 year(s) ago
VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas, featuring leading expert insights
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Chemotherapy: the backbone of lymphoma treatment - 1 year(s) ago
VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas, featuring leading expert insights
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Despite the increasing number of novel agents in #HodgkinLymphoma & #NonHodgkinLymphoma, chemotherapy remains a cornerstone of treatment for #Lymphoma. Check out our new feature on the role of chemotherapy in lymphoma 👉https://t.co/VGifKtdQyR👈 #HemOnc #LYMsm #DLBCL
-
-
Mashup Score: 3CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma - 1 year(s) ago
CD19/CD20 bispecific CAR-T cells enriched in naive and memory phenotypes achieve robust antitumor efficacy and durability of response with minimal toxicity in patients with relapsed and refractory non-Hodgkin lymphoma.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the March issue of Cancer Discovery— CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory #TCells for the Treatment of Relapsed or Refractory #NonHodgkinLymphoma, by Sarah Larson, Yvonne Chen et al. https://t.co/MdJGQvKfBi @UCLAJCCC @dgsomucla @UCLA https://t.co/DEVviyLP6l
-
-
Mashup Score: 0Blood test predicts CAR-T response in non-Hodgkin lymphoma - 1 year(s) ago
A risk model based on low-pass whole-genome sequencing of cell-free DNA predicted which patients are more likely to respond to chimeric antigen receptor T-cell therapy for large B-cell lymphoma, study results showed.Researchers from The University of Texas MD Anderson Cancer Center developed a noninvasive blood-based assay to determine a patient’s level of genomic instability. Investigators
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Blood test predicts CAR-T response in non-Hodgkin lymphoma. https://t.co/L1B9r13spF #carT @ClevelandClinic #ICYMI #HemOnc #OncAlert #MedEd #nonHodgkinlymphoma
-
-
Mashup Score: 0
NEW ORLEANS — Looking at 185 countries, a projection presented at the ASH Annual Meeting and Exhibition suggests the global burden of non-Hodgkin lymphoma will increase by 778,000 cases by 2040.“We saw the growing incident trends in non-Hodgkin lymphoma particularly among the elderly population and the large increase in the incidence may indicate the growing prevalence of risk factors
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Global burden of non-Hodgkin lymphoma estimated to increase 1.5-fold by 2040. https://t.co/18i9ssUvZM @ASH_hematology #HemOnc #OncAlert #MedEd #nonHodgkinLymphoma
-
-
Mashup Score: 0CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma - 1 year(s) ago
Abstract. To address antigen escape and loss of T-cell functionality, we report a phase-1 clinical trial (NCT04007029) evaluating autologous naive and memory T (TN/MEM) cells engineered to express a bispecific anti-CD19/CD20 CAR (CART19/20) for patients with relapsed/refractory NHL, with safety as the primary end point. Ten patients were treated with 36–165 x 106 CART19/20 cells. No patient…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory #TCells for the Treatment of Relapsed or Refractory #NonHodgkinLymphoma, by Sarah Larson, Yvonne Chen et al. https://t.co/lfXzKH4Pnh @UCLAJCCC @dgsomucla @UCLA https://t.co/CWzyXjwKGk
-
-
Mashup Score: 0Diffuse Large B-Cell Lymphoma - Cancer Stat Facts - 1 year(s) ago
Diffuse Large B-Cell Lymphoma statistics
Source: SEERCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Learn about #NonHodgkinLymphoma subtypes such as #DLBCL from our Stat Facts: https://t.co/VPa4HeomnS https://t.co/oBQwi6jZgk
-
-
Mashup Score: 0Study of CAR-T for patients with non-Hodgkin lymphoma, HIV yields 'reassuring' results - 1 year(s) ago
NEW ORLEANS — Chimeric antigen receptor T cells demonstrated acceptable efficacy with no additional safety concerns when administered to patients with non-Hodgkin lymphoma and HIV, retrospective study results showed.Data from an interim analysis of the AIDS Malignancy Consortium Study (AMC-113) — presented at ASH Annual Meeting and Exposition — suggested treatment is safe for
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASH22 Study of CAR-T for patients with non-Hodgkin lymphoma, HIV yields 'reassuring' results. https://t.co/zBvtD2h9ow @ASH_hematology #HemOnc #OncAlert #MedEd #nonHodgkinlymphoma @PerelmanSchoolofMedicine
-
-
Mashup Score: 0
The FDA granted fast track and regenerative medicine advanced therapy designations to CB-010, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. The fast track designation applies to patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The regenerative medicine advanced therapy (RMAT) designation applies to patients
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA FAST TRACK: RMAT designations to CAR-T for advanced non-Hodgkin lymphoma. https://t.co/OlvclyabhF @US_FDA #nonHodgkinLymphoma @CaribouBio #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 2CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma - 1 year(s) ago
Abstract. To address antigen escape and loss of T-cell functionality, we report a phase-1 clinical trial (NCT04007029) evaluating autologous naive and memory T (TN/MEM) cells engineered to express a bispecific anti-CD19/CD20 CAR (CART19/20) for patients with relapsed/refractory NHL, with safety as the primary end point. Ten patients were treated with 36–165 x 106 CART19/20 cells. No patient…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory #TCells for the Treatment of Relapsed or Refractory #NonHodgkinLymphoma, by Sarah Larson, Yvonne Chen et al. https://t.co/WybBtt70WT @UCLAJCCC @dgsomucla @UCLA https://t.co/1tKzaTUfZS
-
Be sure to read our latest article covering the evolving role of chemotherapy in the management of #Lymphoma 👉https://t.co/VGifKtdiJj👈 #HemOnc #LYMsm #DLBCL #HodgkinLymphoma #NonHodgkinLymphoma